Business Monitor International


Morocco Pharmaceuticals & Healthcare Report

Published 01 April 2014

  • 113 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Morocco Pharmaceuticals & Healthcare Report

BMI View: We expect poor economic conditions in Morocco will lead to continuing decline in pharmaceutical imports and spending in the short term. However, the rate of decline in pharmaceutical sales is starting to slow, indicating that conditions for Moroccan drugmakers are beginning to improve as the growing middle class drives demand. Our outlook is therefore more positive over the long term. Meanwhile, the patented drugs market will continue to take the largest percentage of overall pharmaceutical sales, but will start to lose its share of the total as the government continues to promote the use of generic products, leading to increased substitution of branded drugs.

Headline Expenditure Projections

  • Pharmaceuticals: MAD9.32bn (US$1.11bn) in 2013 to MAD9.49bn (US$1.13bn) in 2014; +1.7% in local currency terms and +2.0% in US dollar terms.

  • Healthcare: MAD54.83bn (US$6.53bn) in 2013 to MAD56.48bn (US$6.74bn) in 2014; +3.0% in local currency terms and +3.2% in US dollar terms. Forecast higher than Q413 on account of upward revision of historical figures for pharmaceutical market.

Risk/Reward Rating

In our latest proprietary Pharmaceutical Risk/Reward Ratings (RRR), Morocco continues to be viewed as a moderately attractive pharmaceutical market in the Middle East and Africa (MEA) region, from a longer-term perspective. Morocco ranks 13 th in the region, out of the 30 countries assessed in our ratings matrix, with a score of 42.3 out of 100. The market's constraints include low per capita consumption and an underdeveloped reimbursement system, although such factors are to a degree offset by a relatively predictable operating environment.

Key Trends And Developments

  • Moroccan drugmakers are seeking to enter the UAE's pharmaceutical market, The National reported in Febraury 2014, citing export adviser for Maroc Export, Hamid Kabbage. Two companies that plan to enter the market this year are Pharma5, which expects to enter the market with five medicines...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Morocco Pharmaceutical Sales, Historical Data and Forecasts
16
Healthcare Market Forecast
17
Table: Morocco Healthcare Expenditure Trends, Historical Data and Forecasts
18
Table: Morocco Government Healthcare Expenditure Trends, Historical Data and Forecasts
18
Table: Morocco Private Healthcare Expenditure Trends, Historical Data and Forecasts
19
Prescription Drug Market Forecast
19
Table: Morocco Prescription Drug Market Indicators, Historical Data and Forecasts
20
Patented Drug Market Forecast
21
Table: Morocco Patented Drug Market Indicators, Historical Data and Forecasts
22
Generic Drug Market Forecast
23
Table: Morocco Generic Drug Market Indicators, Historical Data and Forecasts
25
OTC Medicine Market Forecast
25
Table: Morocco Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts
26
Pharmaceutical Trade Forecast
27
Table: Morocco Pharmaceutical Trade Data And Forecasts (US$mn)
29
Table: Morocco Pharmaceutical Trade Data And Forecasts (MADmn)
29
Other Healthcare Data
29
Key Risks To BMI's Forecast Scenario
30
Macroeconomic Forecasts
32
Economic Analysis
32
Table: Morocco - Real Growth By Sector, % chg y-o-y
33
Table: Morocco - GDP By Expenditure, Real Growth %
41
Industry Risk Reward Ratings
42
Middle East And Africa Risk/Reward Ratings
42
Morocco Risk/ Reward Ratings
50
Rewards
50
Risks
51
Market Overview
53
Industry Trends And Developments
54
Epidemiology
54
Healthcare Sector
57
Healthcare Insurance
60
Recent Health Insurance Developments
63
Research & Development
66
Clinical Trials
67
Regulatory Development
68
Intellectual Property Regime
69
Pricing Regime
69
Reimbursement Regime
71
Competitive Landscape
74
Pharmaceutical Industry
74
Table: Morocco's Select Pharmaceutical Industry Indicators
74
Table: Members Of MIS, 2011
75
Table: Members Of AMIP, 2011
76
Domestic Pharmaceutical sector
76
Foreign Pharmaceutical Companies
77
Pharmaceutical Wholesale
79
Pharmaceutical Retail
80
Company Profile
82
Sothema
82
Laprophan
85
Promopharm
88
Sanofi
90
Pfizer
94
GlaxoSmithKline
97
Ranbaxy
99
Demographic Forecast
101
Demographic Outlook
101
Table: Morocco's Population By Age Group, 1990-2020 ('000)
102
Table: Morocco's Population By Age Group, 1990-2020 (% of total)
103
Table: Morocco's Key Population Ratios, 1990-2020
104
Table: Morocco's Rural And Urban Population, 1990-2020
104
Glossary
105
Methodology
107
Pharmaceutical Expenditure Forecast Model
107
Healthcare Expenditure Forecast Model
107
Notes On Methodology
108
Risk/Reward Ratings Methodology
109
Ratings Overview
110
Table: Pharmaceutical Risk/Reward Ratings Indicators
110
Indicator Weightings
111

The Morocco Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Morocco Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Moroccan pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Morocco to test other views - a key input for successful budgeting and strategic business planning in the Moroccan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Moroccan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Morocco.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc